

Special Issue

Virus-Like Particles in Vaccine and Cancer Immunotherapy

Message from the Guest Editor

Virus-like particles (VLPs) are replication-incompetent vaccines that represent an intact, non-replicative virion lacking a genome but maintaining the original antigenic composition of the surface proteins incorporated into the virion's outer membrane. VLPs have unique properties as particulate immunogens due to their size and pseudoviral structure, which may correctly present linear and conformational epitopes to the immune system to elicit both humoral and cellular immune responses. Therefore, it is an attractive approach and has been widely used for infectious disease vaccines and for cancer immunotherapies. This Special Issue focuses on "Virus-like Particles in Vaccine and Cancer Immunotherapy". Submissions of original articles, systematic reviews, short communications, and other types of articles on related topics are welcome. All manuscripts will follow standard journal peer-review practices, and those accepted for publication will appear in the issue "Virus-like Particles in Vaccine and Cancer Immunotherapy". We look forward to receiving your contributions to the Special Issue.

Guest Editor

Prof. Dr. Qizhi Cathy Yao

1. Michael E. DeBakey Department of Surgery, Division of Surgical Oncology, Baylor College of Medicine, Houston, TX 77030, USA
2. Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (31 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/107649

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).